Abstract Reperfusion therapy for ischemic stroke can cause secondary brain injury, especially under hyperglycemic (HG) conditions. Here, we investigated the effect of acute treatment with rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, prior to postischemic reperfusion, on stroke outcome during HG stroke. Male Wistar rats that were either normoglycemic (NG) or HG by STZ (50 mg/kg; for 5-6 days) underwent middle cerebral artery occlusion (MCAO) for 2 h with 2 h of reperfusion. Animals were treated i.v. with rosiglitazone (1 mg/kg; n016), rosiglitazone (1 mg/kg)+the free radical scavenger Tempol (50 mg/kg; n010) or vehicle (n016) 10 min prior to reperfusion and infarct volume, edema formation, and cerebral blood flow (CBF) were measured. Compared to NG, HG stroke significantly increased infarct volume from 5.2±3.0 % vs. 14.7±3.6 % (p<0.05). Rosiglitazone prevented the increased infarct volume induced by HG that was only 6.9±2.0 % (p<0.05 vs. HG) but did not have any effect on edema formation that was increased by 3.0 % in both HG vehicle and rosiglitazone-treated ipsilateral vs. contralateral hemispheres (p < 0.05). Combined treatment of rosiglitazone+Tempol did not significantly change brain water content that remained 2.2 % greater than contralateral (p < 0.05) but reversed the neuroprotective properties of rosiglitazone in HG MCAO animals such that infarct volume was 14.3±4.4 % (p>0.05 vs. vehicle). The lack of an effect of combined treatment of rosiglitazone+ Temple may be due to a decrease in reperfusion CBF that was only 60 % of baseline (p<0.01) compared to 82 % and 89 % for HG vehicle and rosiglitazone-treated animals (p> 0.05). In conclusion, acute rosiglitazone treatment prior reperfusion was neuroprotective but not vascular protective during HG stroke.
Introduction
Despite some progress in understanding the pathophysiology of ischemic stroke, the success in stroke treatment has largely failed. Reperfusion of the ischemic brain by rapid recanalization of an occluded vessel is currently the only effective therapy for ischemic stroke [1] . However, postischemic reperfusion is not entirely beneficial. The window of opportunity for improvement of stroke outcome is brief (<6 h), after which reperfusion can result in cerebral injury [2] . Reperfusion injury is especially prevalent in hyperglycemic (HG) ischemic stroke [3] , suggesting hyperglycemia may be an important factor in brain damage after reperfusion. Compared to normoglycemia, hyperglycemia significantly worsens stroke outcome, including larger infarction, edema formation, and a higher risk of mortality [4, 5] . Hyperglycemia fundamentally exacerbates brain damage by altering vascular responses [6, 7] . In addition, hyperglycemia induces pro-inflammatory, pro-thrombotic, and provasoconstrictive changes in the vasculature that impair autoregulation and postischemic reperfusion blood flow [6] . In the complexity of hyperglycemia's effects after ischemia/reperfusion (I/R), inflammation and oxidative stress appear to be important key mechanisms. Thus, reactive oxygen species (ROS) and pro-inflammatory factors found in HG stroke are higher than in normoglycemic conditions [8, 9] .
Rosiglitazone, an agonist of the ligand-activated transcription factor peroxisome proliferator-activated receptorgamma (PPAR-γ), has been shown to possess antiinflammatory [10, 11] and antioxidant [12, 13] properties, including in the vasculature. Although chronic treatment of diabetic patients with rosiglitazone has increased risk of cardiovascular disease, including stroke [14] , the use of rosiglitazone for acute treatment such as reperfusion injury appears to be beneficial. Experiments in vivo have shown a neuroprotective effect of rosiglitazone when animals are treated prior to or after the induction of focal or global cerebral ischemia [15] . However, if rosiglitazone is protective during reperfusion is not known, especially during HG stroke when oxidative stress is high. In the present study, we investigated if acute rosiglitazone treatment 10 min prior to postischemic reperfusion would improve infarction and edema formation during HG stroke. We also investigated if combined treatment with rosiglitazone plus the antioxidant Tempol would provide greater protection during HG stroke.
Materials and Methods

Animal Model of Transient Focal Ischemia
All procedures were approved by the Institutional Animal Care and Use Committee and complied with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All animals were male Wistar rats (∼300 g) that were either normoglycemic (NG) or HG. Animals were made HG by a single intraperitoneal injection of streptozotocin (50 mg/kg) 5-6 days prior to middle cerebral artery occlusion (MCAO), as previously described [16] . Glucose was measured on the day of the surgery by a commercially available glucose monitor (Freestyle Lite, Abbott, Abbott Park, IL). Animals that had blood glucose levels of <280 mg/dL were excluded from the study (see Table 1 ).
Temporary filament occlusion of the middle cerebral artery (MCA) was used to induce I/R in both NG and HG animals, as previously described [16, 18] . Animals were anesthetized with isoflurane in oxygen and ventilated to maintain blood gases within normal ranges (see Table 1 ). NG and HG animals were exposed to 2 h of ischemia and 2 h of reperfusion by suture removal. Cerebral blood flow (CBF) was continuously measured during MCAO and for 2 h of reperfusion using laser Doppler flowmetry (Perimed Periflux 5010 Laser Doppler System), as previously described [16, 18] . Briefly, after initial anesthesia but before midline incision for placement of the monofilament, a skin incision was made and the microtip of the laser-Doppler fiber-optic probe was affixed over a thinned area of skull posterior to the coronal suture and lateral to the sagittal suture over the MCA perfusion domain. The probe was left in place, and CBF was recorded during the experiment. Laser Doppler was used to measure changes in CBF from baseline, including both the decrease in CBF during occlusion and the extent of reperfusion after suture removal.
Experimental Protocols and Drug Treatments
In the first set of experiments, both NG and HG animals were infused intravenously via femoral catheter with the PPAR-γ agonist rosiglitazone (1 mg/kg, n013) or vehicle (saline; n013) 10 min prior to reperfusion, as previously described [17] . At the end of the reperfusion period, the animals were decapitated and the brains removed for measurement of acute infarction. Acute infarct volume was measured using 2,3,5-triphenyltetrazolium chloride (TTC) staining. Briefly, brains were removed and sliced into 2 mm coronal sections. The brain slices were incubated in 2 % TTC in 1× phosphate buffered saline (PBS) for 30 min at 36.5°C to stain for infarction. The brain slices were subsequently fixed in 3.7 % PBS-buffered formalin for 30 min at 4°C for imaging. Images were captured using a digital scanner and analyzed for acute injury volume with ImageJ software. The percent of infarcted brain tissue in the ipsilateral hemisphere was corrected for edema by calculating the percent infarct volume after the area of each contralateral brain section was subtracted from the ipsilateral.
In the second set of experiments, HG animals only (n06) underwent MCAO for measurement of vasogenic edema using wet and dry weights. At the end of the reperfusion period, the animals were decapitated and the brain removed for measurement of water content, as previously described [16] . Briefly, ipsilateral and contralateral cerebral cortex (brainstem and cerebellum removed) were weighed wet then dried overnight at 90°C . The brain sections were then weighed dry, and the ratio of wet to dry weight for each hemisphere was used as a measure of edema.
In the third set of experiments, a combined treatment of rosiglitazone (1 mg/kg)+the free radical scavenger Tempol (50 mg/kg; n010) was given intravenously 10 min prior to reperfusion and infarction and edema formation measured, as described above. Drugs TTC, formalin, and Tempol were purchased from Sigma (St Louis, MO, USA). Rosiglitazone was purchased from Cayman Chemicals (Ann Arbor, MI).
Data calculations and Statistical Analysis
Results are presented as mean±SEM. Acute infarct volume was corrected for brain edema and calculated as: ([wet weight −dry weight]/wet weight)×100 %. Percent water content was compared between ipsilateral and contralateral sides of the brain using paired t test. Reperfusion CBF was determined from laser Doppler units as a percent change from baseline CBF. Differences between individual groups were determined using one-way analysis of variance (ANOVA) with a posthoc Student-Newman-Keuls test for multiple comparisons, where appropriate. Differences were considered significant when p<0.05.
Results
Effect of Rosiglitazone on Infarct Volume
Hyperglycemia has been shown to worsen stroke outcome [4, 5] . In the present study, we compared infarct volume in normoglycemic (NG) or hyperglycemic (HG) animals that underwent MCAO for 2 h and 2 h of reperfusion. Figure 1 shows that infarct volume was significantly increased in HG animals, demonstrating a detrimental effect of hyperglycemia on infarct formation during stroke.
To test rosiglitazone as potential therapy for reperfusion injury, we treated NG and HG animals that underwent 2 h of MCAO and 2 h reperfusion with 1 mg/kg rosiglitazone 10 min prior reperfusion. Figure 1 shows that acute rosiglitazone treatment prevented the increase in infarct volume in 
Effect of Rosiglitazone on Brain Water Content
We have previously shown that hyperglycemia significantly increases water content in the ipsilateral brain after MCAO compared to NG animals [17] . To determine if acute rosiglitazone treatment, that was neuroprotective during HG stroke (Fig. 1) , could decrease blood-brain barrier (BBB) permeability and prevent edema formation, a separate group of animals was treated with rosiglitazone prior to post-ischemic reperfusion and brain water content measured. Figure 2 shows that acute rosiglitazone treatment 10 min prior to reperfusion did not affect edema formation induced by HG stroke, suggesting that rosiglitazone is not vascular protective.
Effect of Rosiglitazone and Tempol on Infarct Volume and Brain Water Content
It is well known that oxidative stress is an important mechanism in the pathophysiology of HG stroke, especially during reperfusion [6, 9] . Thus, to protect the vasculature in addition to neurons during stroke, we combined rosiglitazone treatment with the free radical scavenger Tempol (50 mg/kg). We found that treatment of HG MCAO animals with the combined treatment of rosiglitazone + Tempol 10 min prior reperfusion did not have a significant effect on the ipsilateral water content compared to HG vehicle (Fig. 3a) . Moreover, rosiglitazone+Tempol treatment prevented the neuroprotective properties of rosiglitazone alone, and the acute injury volume was not different from vehicle treated animals (Fig. 3b) .
Effect of MCAO and Rosiglitazone on Reperfusion CBF
Because the effects of rosiglitazone or rosiglitazone+Tem-pol on stroke outcome can be due to changes in CBF and an effect on reperfusion blood flow, we compared CBF prior to and after MCAO in HG animals treated with rosiglitazone alone or the combination of rosiglitazone+Tempol. Figure 4 shows changes in relative CBF during 2 h of MCAO and 2 h of reperfusion. There was no difference in the depth of ischemia that was maintained for the duration of occlusion (2 h). However, while reperfusion resulted in recanalization in all groups, it was significantly decreased in rosiglitazone +Tempol-treated animals, suggesting combined treatment may worsen infarct volume by limiting reperfusion CBF.
Discussion
The present study investigated the effect of acute rosiglitazone treatment 10 min prior to post-ischemic reperfusion on acute infarction and edema formation during HG stroke. We found that rosiglitazone prevented the increase in acute injury volume but not edema formation induced by hyperglycemia, suggesting that rosiglitazone is neuroprotective but not vascular protective under these conditions. Combined treatment of rosiglitazone plus Tempol also failed to protect the vasculature and reversed the neuroprotective effect of rosiglitazone alone, possibly by decreasing reperfusion CBF (Fig. 4) . Together, these results suggest that while rosiglitazone may be neuroprotective in the acute setting after HG stroke, it does not prevent edema formation. In addition, combined therapy with Tempol does not appear to be an effective approach to treating HG stroke. Reperfusion of the ischemic tissue is important to salvage brain tissue and decrease morbidity and mortality due to stroke. However, reperfusion itself also result in a cascade of adverse reactions that paradoxically injure tissue, a phenomenon termed "reperfusion injury". Inflammation and oxidative stress represent important mechanisms in the pathogenesis of reperfusion injury [6, 19, 20, 21] . The restored blood flow reintroduces oxygen that provides an abundant substrate to ROS [6] as well as blood-borne leukocytes that secrete cytokines and also release ROS, promoting further brain injury [20, 21] . Reperfusion injury is exacerbated in HG ischemic stroke [3] , possibly by increasing ROS and inflammatory factors [8, 9] . The use of rosiglitazone in focal or global cerebral ischemia has been investigated previously. In these previous studies, treatment was given prior to or after ischemic stroke and under normoglycemic conditions [11, 15] . This study is the first Fig. 2 Effect of rosiglitazone on brain edema during hyperglycemic (HG) MCAO. Graph showing brain water content in ipsilateral and contralateral hemispheres from HG animals that underwent 2 h of ischemia with 2 h of reperfusion and treated acutely with either rosiglitazone (Rosi) or vehicle. Rosiglitazone did not affect the increased water content in the ipsilateral hemisphere during HG MCAO, suggesting that it is not effective in vascular protection. *p<0.01 versus contralateral evidence demonstrating the neuroprotective effects of rosiglitazone during reperfusion in HG stroke animals. A limitation of this study is that we have not determined the mechanism by which rosiglitazone is neuroprotective. However, because rosiglitazone possess anti-inflammatory [10, 11] and antioxidant [12, 13] properties, it is possible that rosiglitazone improved stroke outcome by affecting inflammatory and oxidative stress processes. In fact, it has been shown that PPAR-γ agonists decrease neutrophil accumulation and pro-inflammatory proteins such as tumor necrosis factor-alpha, interleukin (IL)-1beta, and IL-6 in a focal ischemic brain model [22] and attenuated ischemiainduced ROS by increasing superoxide dismutase/catalase and decreasing nicotinamide adenine dinucleotide phosphate (NADPH) oxidase levels [23] . It is worth noting that we measured infarction after 2 h of reperfusion, an acute time period. Thus, it is unclear what the final infarct may evolve into and we cannot exclude that the neuroprotection seen with rosiglitazone was only temporary.
Rosiglitazone did not reduce brain edema in HG stroke animals, suggesting that it was not vascular protective since vasogenic edema results from increased BBB permeability. Diabetic patients treated with rosiglitazone can develop fluid retention and edema [24] . Although the underlying mechanisms are unclear, it has been proposed that rosiglitazone-induced edema can be a result of increased vascular permeability by a direct effect on endothelial barrier function [25] , by activating protein kinase C (PKC) [26] and/or by increasing expression of permeability agents such as vascular endothelial growth factor (VEGF) [26, 27] . These effects of rosiglitazone on vascular permeability may explain why rosiglitazone was not vascular protective in HG stroke animals. In contrast, Xiong et al. [28] have shown that the effect of rosiglitazone in brain swelling is dose-dependent. While 0.5 mg/kg had no effect, 2 and 5 mg/ kg of rosiglitazone administrated immediately and 2 h after MCAO significantly reduced brain swelling [28] . Thus, it is also possible that the concentration of rosiglitazone used in these experiments (1 mg/kg) may not have been high enough to be effective for vascular protection. Because oxidative stress is high during cerebral I/R especially under HG conditions [9] , we also investigated if combined treatment with rosiglitazone plus the antioxidant Tempol would provide greater protection during HG stroke. We used a dose of Tempol of 50 mg/kg which was somewhat higher than Shown are animals treated 10 min prior to reperfusion with rosiglitazone alone, rosiglitazone+Tempol or vehicle. All treatment groups had similar ischemia during filament occlusion; however, rosiglitazone+ Tempol treatment 10 min prior reperfusion significantly decreased reperfusion CBF. **p<0.01 versus baseline others have shown to be neuroprotective during MCAO under normoglycemic conditions, i.e., 20 mg/kg [29] . This dose was used because of the high oxidative stress associated with HG stroke. However, administration of rosiglitazone+Tempol prior reperfusion was not vascular protective. Moreover, combined treatment reversed the neuroprotective properties of rosiglitazone alone. Although we have not investigated the mechanism by which rosiglitazone+Tem-pol prevented neuroprotection, since rosiglitazone+Tempol significantly decreased CBF during reperfusion, it is possible that the decrease in reperfusion could increase infarction. In addition, it has been shown that under certain conditions, Tempol has the potential to increase oxidant stress in cells and tissues including vascular smooth muscle and endothelial cells [30, 31] . Thus, we cannot exclude a pro-oxidant effect of Tempol that can increase oxidative stress and worsen brain infarct in our experimental conditions. Although it is possible that the dose of Tempol used was too high in the present study, the concentration used was not all that much higher than has been shown to be protective during stroke under normoglycemic conditions. Thus, it is possible that the high oxidative stress associated with postischemic reperfusion under HG conditions renders Tempol ineffective or pro-oxidant, worsening outcome either through enhanced ROS and/or decreased reperfusion CBF.
In conclusion, we have shown that acute rosiglitazone treatment during reperfusion is neuroprotective but not vascular protective in HG ischemic stroke. While protection of the neurons from hypoxic/ischemic injury is undoubtedly important, stroke is a vascular disorder affecting not only neurons, but other cell types including vascular cells. Thus, further investigations are needed to find a successful stroke therapy that protects not only neurons but also the vasculature.
